What’s New in Acne Management: What We Have Learned from Increased Understanding of Acne Pathophysiology

Featured Article

What's New in Acne Management:

What We Have Learned From Increased Understanding of Acne Pathophysiology

Join Drs. Leon H. Kircik, Linda Stein Gold, and Jonathan S. Weiss as they discuss the medical interventions generally targeting one or more of the key factors contributing to the development of acne lesions: follicular hyperproliferation and abnormal desquamation (topical and oral retinoids, azelaic acid, salicylic acid, hormonal therapy), increase sebum production (oral isotretinoin, hormonal therapy), C. acnes proliferation (benzoyl peroxide, topical and oral antibiotics, azelaic acid) and inflammation (oral isotretinoin, oral tetracyclines, topical retinoids, azelaic acid).

Acne pathogenesis is multifactorial and not clearly understood; a key factor includes genetics and may result as in interplay of release of inflammatory mediators into the skin, follicular hyperkeratinization with subsequent plugging of the follicle, Cutibacterium acne (C. acnes), formerly Propionibacterium acnes or P. acnes, follicular colonization and excess sebum production.

C. acnes has been shown to mediate inflammatory processes at the site of the sebaceous follicle contributing to the formation of free radical species and generating pro-inflammatory cytokines. Excess sebum production and C. acnes colonization lead to the formation of microcomedones leading to the development of open or closed comedones, inflammatory papules, pustules and cysts characteristic of acne.

Acne severity and grade (comedonal, papulopustular, mixed, nodular), skin type, presence of acne scarring and postinflammatory hyperpigmentation, menstrual cycle history (in women), skin current skin care regimen are factors influencing treatment with classes of topical agents include: comedolytic (anticomedogenic), antimicrobial, antibiotic and antiinflammatory; each impact on the four main pathogenic features of acne.

FACULTY

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana University School of Medicine
Mount Sinai Medical Center, New York, NY
Physicians Skin Care, PLLC
Louisville, KY

Linda Stein Gold, MD
Director, Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan

Jonathan S. Weiss, MD
Adjunct Assistant Clinical Professor of Dermatology
Emory University School of Medicine
Atlanta, GA
President & Co-Managing Partner
Georgia Dermatology Partners
(Formerly, Gwinnett Dermatology, PC)

Watch Now

Efficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study

Mikaela Sonis | Aesthetics, Dyspigmentation, Featured Articles, Latest News | No Comments

Topical Metformin versus Kligman’s Formula for Melasma, a Split-Face JDD Study This is a must-read article from JDD a head-to-head split-face study asks whether topical metformin can be an effective,…

Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study

Mikaela Sonis | Featured Articles, Latest News, Oncodermatology, Skin Cancer | No Comments

Extended Pembrolizumab Duration Tied to Lower Mortality in Stage III and IV Melanoma: JDD Report Could extending pembrolizumab improve survival? This JDD is a must read. A new retrospective analysis…

Clinical Methodology to Evaluate the Efficacy of a Topical Cosmetic Eye Formulation on the Appearance of Dynamic Periorbital Lines

Mikaela Sonis | Aesthetics, Featured Articles, Latest News, Skincare | No Comments

New JDD Study Introduces Objective Method for Measuring Periorbital Dynamic Lines For dermatology teams focused on antiaging care, this article from the JDD is a must read. Dermatologists and clinical…

Tags:

Featured Article